학술논문
Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study
Document Type
Article
Author
Source
In The Lancet Rheumatology November 2020 2(11):e677-e688
Subject
Language
ISSN
2665-9913